Nurix Therapeutics (NRIX) Preferred Stock Liabilities (2019 - 2020)
Nurix Therapeutics' (NRIX) quarterly Preferred Stock Liabilities came in at $168.1 million in Q2 2020, up 248.81% on a QoQ basis from $48.2 million in Q1 2020.
Nurix Therapeutics (NRIX) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
Nurix Therapeutics (NRIX) has 2 years of Preferred Stock Liabilities data on file, last reported at $168.1 million in Q2 2020.
- On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $168.1 million in Q2 2020; TTM through May 2020 was $168.1 million, a N/A change from a year earlier, with the FY2019 full-year figure at $48.2 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q2 2020 stood at $168.1 million, up from $48.2 million in the prior quarter.
- Over the last five years, Preferred Stock Liabilities for NRIX reached as high as $168.1 million in Q2 2020 and fell as low as $48.2 million in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Nurix Therapeutics | 2.64 Bn | 2.19 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2020 | 168.11 Mn |
| Feb 29, 2020 | 48.20 Mn |
| Nov 30, 2019 | 48.20 Mn |
| Aug 31, 2019 | 48.20 Mn |